Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5362-5370

  McGivern, David R ^a   Masaki, Takahiro ^a,c   Lovell, William ^a   Hamlett, Chris ^b   Saalau Bethell, Susanne ^b   Graham, Brent ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AT 23708; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CARRIER PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; OLIGOPEPTIDE; VIRUS PROTEIN; VIRUS RNA;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; HEPATITIS C VIRUS; IMMUNOBLOTTING; LIFE CYCLE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA SYNTHESIS; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS INHIBITION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; HEPACIVIRUS; HUMAN; KINETICS; METABOLISM; PHYSIOLOGY;

APHIS; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE; HEPACIVIRUS; HUMANS; KINETICS; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS ASSEMBLY;

EID: 84928567969     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03188-14     Document Type: Article

References (38)

1. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19:837-849. http://dx.doi.org/10.1038/nm.3248.
2. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102: 17717-17722. http://dx.doi.org/10.1073/pnas.0508531102.
3. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Jr, Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102:2992-2997. http://dx.doi.org/10.1073/pnas.0408824102.
4. Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD. 2013. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother 57: 4417-4426. http://dx.doi.org/10.1128/AAC.00399-13.
5. Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, Pyles RB, Bourne N, Yi M, Li K, Lemon SM. 2008. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135:1710-1718.e1712. http://dx.doi.org/10.1053/j.gastro.2008.07.023.
6. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50:1013-1020. http://dx.doi.org/10.1128/AAC.50.3.1013-1020.2006.
7. Lin K, Perni RB, Kwong AD, Lin C. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50:1813-1822. http://dx.doi.org/10.1128/AAC.50.5.1813-1822.2006.
8. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B, Vrang L, de Kock H, Wigerinck P, Raboisson P, Simmen K. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377-1385. http://dx.doi.org/10.1128/AAC.01058-08.
9. Rosenquist A, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-Mauviel M. 2014. Discovery and development of simeprevir (TMC435), aHCVNS3/4A protease inhibitor. J Med Chem 57:1673-1693. http://dx.doi.org/10.1021/jm401507s.
10. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161-4167. http://dx.doi.org/10.1128/AAC.00324-12.
11. Pang PS, Jankowsky E, Planet PJ, Pyle AM. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J 21:1168-1176. http://dx.doi.org/10.1093/emboj/21.5.1168.
12. Lam AM, Frick DN. 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 80:404-411. http://dx.doi.org/10.1128/JVI.80.1.404-411.2006.
13. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. 2008. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol 82:7624-7639. http://dx.doi.org/10.1128/JVI.00724-08.
14. Beran RK, Serebrov V, Pyle AM. 2007. The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J Biol Chem 282:34913-34920. http://dx.doi.org/10.1074/jbc.M707165200.
15. Beran RK, Pyle AM. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 283:29929-29937. http://dx.doi.org/10.1074/jbc.M804065200.
16. Morgenstern KA, Landro JA, Hsiao K, Lin C, Gu Y, Su MS, Thomson JA. 1997. Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells. J Virol 71:3767-3775.
17. Kohlway A, Pirakitikulr N, Ding SC, Yang F, Luo D, Lindenbach BD, Pyle AM. 2014. The linker region of NS3 plays a critical role in the replication and infectivity of hepatitis C virus. J Virol 88:10970-10974. http://dx.doi.org/10.1128/JVI.00745-14.
18. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, Graham B, Hiscock SD, Murray CW, Pathuri P, Rich SJ, Richardson CJ, Williams PA, Jhoti H. 2012. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 8:920-925. http://dx.doi.org/10.1038/nchembio.1081.
19. Aydin C, Mukherjee S, Hanson AM, Frick DN, Schiffer CA. 2013. The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. Protein Sci 22:1786-1798. http://dx.doi.org/10.1002/pro.2378.
20. Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM. 2004. Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol 78:1513-1524. http://dx.doi.org/10.1128/JVI.78.3.1513-1524.2004.
21. Li K, Chen Z, Kato N, Gale M, Jr, Lemon SM. 2005. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 280:16739-16747. http://dx.doi.org/10.1074/jbc.M414139200.
22. Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitisCvirus. Hepatology 49:745-752. http://dx.doi.org/10.1002/hep.22717.
23. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM. 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140:667-675. http://dx.doi.org/10.1053/j.gastro.2010.10.056.
24. Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM. 2014. Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 88:3678-3694. http://dx.doi.org/10.1128/JVI.03540-13.
25. Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. 2011. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 85:7989-8001. http://dx.doi.org/10.1128/JVI.00280-11.
26. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM. 2014. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:453-462.e457. http://dx.doi.org/10.1053/j.gastro.2014.04.021.
27. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitisCvirus production. Nat Cell Biol 9:1089-1097. http://dx.doi.org/10.1038/ncb1631.
28. Frick DN, Rypma RS, Lam AM, Gu B. 2004. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J Biol Chem 279:1269-1280. http://dx.doi.org/10.1074/jbc.M310630200.
29. Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN. 2012. Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. Antiviral Res 96:245-255. http://dx.doi.org/10.1016/j.antiviral.2012.08.006.
30. Ding SC, Kohlway AS, Pyle AM. 2011. Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus. J Virol 85:4343-4353. http://dx.doi.org/10.1128/JVI.02130-10.
31. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. 2013. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110:3991-3996. http://dx.doi.org/10.1073/pnas.1203110110.
32. Jones DM, Atoom AM, Zhang X, Kottilil S, Russell RS. 2011. A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus. J Virol 85:12351-12361. http://dx.doi.org/10.1128/JVI.05313-11.
33. Mousseau G, Kota S, Takahashi V, Frick DN, Strosberg AD. 2011. Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase. J Gen Virol 92:101-111. http://dx.doi.org/10.1099/vir.0.023325-0.
34. Neddermann P, Clementi A, De Francesco R. 1999. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol 73:9984-9991.
35. Horner SM, Liu HM, Park HS, Briley J, Gale M, Jr. 2011. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc Natl Acad Sci U S A 108:14590-14595. http://dx.doi.org/10.1073/pnas.1110133108.
36. Horner SM, Gale M, Jr. 2013. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19:879-888. http://dx.doi.org/10.1038/nm.3253.
37. Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R. 2014. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 147:1094-1105.e25. http://dx.doi.org/10.1053/j.gastro.2014.07.019.
38. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. 2011. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 18:305-315. http://dx.doi.org/10.1111/j.1365-2893.2011.01451.x.